Shield Therapeutics plc (LON:STX – Get Free Report) fell 1.8% during mid-day trading on Wednesday. The stock traded as low as GBX 5.40 and last traded at GBX 5.50. 1,291,653 shares changed hands during mid-day trading, a decline of 45% from the average session volume of 2,352,387 shares. The stock had previously closed at GBX 5.60.
Shield Therapeutics Stock Performance
The firm’s fifty day moving average price is GBX 4.90 and its 200-day moving average price is GBX 6.30. The company has a current ratio of 0.75, a quick ratio of 2.16 and a debt-to-equity ratio of -146.28. The company has a market cap of £59.08 million, a P/E ratio of -5.50 and a beta of 1.77.
About Shield Therapeutics
Shield is a commercial-stage specialty pharmaceutical company that delivers Accrufer®/Feraccru® (ferric maltol), an innovative and differentiated pharmaceutical product, to address a significant unmet need for patients suffering from iron deficiency, with or without anemia. The Company has launched Accrufer® in the U.S. with an exclusive, multi-year commercial agreement with Viatris Inc (Viatris). Outside of the U.S., the Company has licensed the rights to four specialty pharmaceutical companies.
See Also
- Five stocks we like better than Shield Therapeutics
- Skydance Just Became a Media Giant—With an $80 Billion Debt Load
- Could Velo3D Be the Next Defense Buyout Target?
- Penguin Solutions Is Soaring as AI Memory Demand Explodes
- Alphabet’s Chart Is Coiling—and the Fundamentals May Be Ready to Back It Up
Receive News & Ratings for Shield Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Shield Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
